title: Sialic acid level reflects the disturbances of glycosylation and acute-phase reaction in rheumatic diseases.
abstract: In the rheumatic diseases, the changes in the carbohydrate part of serum glycoproteins occur and these abnormalities can be monitored by serum level of total and free sialic acid. The aim of this study was to evaluate the total and free sialic acid level as a marker of inflammation activity (TSA) and the changes in glycosylation of blood glycoproteins (FSA) in rheumatoid arthritis (RA), systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). Studies were carried out in 50 patients with RA, 24 with SLE and 32 with SSc. TSA concentration was measured with an enzymatic, colorimetric method and FSA with a thiobarbituric method. The serum levels of TSA in RA and SLE patients were significantly increased compared to controls and in RA patients were higher than that in SSc patients. The mean serum level of FSA in RA patients was significantly higher, but in SSc patients significantly lower than that in the controls, and in RA patients was significantly higher than in SLE and in SSc patients. All acute-phase proteins were changed: Positive acute-phase proteins were elevated, and the negative protein was decreased. The positive acute-phase proteins positively correlated with the levels of TSA and FSA in RA and SSc patients. In SLE patients, TSA positively correlated with haptoglobin and α1-antitrypsin. In RA patients, there was the positive correlation of TSA and FSA with DAS 28. The changes in the serum levels of TSA and FSA in the course of rheumatic diseases could reflect the abnormalities in glycosylation/sialylation patterns of glycoproteins induced by acute-phase response.
authors.affiliation: Department of Biochemical Diagnostics, Medical University, Waszyngtona 15A, 15-269, Bialystok, Poland, chrostek@umb.edu.pl.
authors.forename: Lech
authors.initials: L
authors.lastname: Chrostek
authors.forename: Bogdan
authors.initials: B
authors.lastname: Cylwik
authors.forename: Ewa
authors.initials: E
authors.lastname: Gindzienska-Sieskiewicz
authors.forename: Ewa
authors.initials: E
authors.lastname: Gruszewska
authors.forename: Maciej
authors.initials: M
authors.lastname: Szmitkowski
authors.forename: Stanislaw
authors.initials: S
authors.lastname: Sierakowski
mesh_terms: D000209:Acute-Phase Proteins / Q000378:metabolism; D000210:Acute-Phase Reaction / Q000097:blood*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001172:Arthritis, Rheumatoid / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006031:Glycosylation; D006242:Haptoglobins / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019158:N-Acetylneuraminic Acid / Q000097:blood*; D012595:Scleroderma, Systemic / Q000097:blood*; D000515:alpha 1-Antitrypsin / Q000097:blood
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; D006023:Glycoproteins; D006242:Haptoglobins; D000515:alpha 1-Antitrypsin; D019158:N-Acetylneuraminic Acid